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Screening for congenital hypothyroidisIn in South Africa
Report on a national workshop (1992)
F ollowing the first national workshop on congenitalhypothyroidism held in Cape Town in May 1987,it was thought appropriate to again review the
progress made in this field over recent years, and espe-
cially to exchange views and consider reco=endations
relating to the screening for congenital hypothyroidism
in South Africa. For this purpose a follow-up workshop
was arranged (23 June 1992, at Jan Smuts Airpon)
under the joint auspices of the National Pathologists
Group of the Medical Association of South Africa and
Genetic Services of the Department of National Health
and Population Development.
The workshop was open to all those known to be
directly involved with or interested in any aspect of con-
genital hypothyroidism. Following the greater participa-
tion of private chemical pathology laboratories in the
screening of newborns for hypothyroidism over recent
years, it was gratifYing to also welcome several represen-
tatives of this professional group. In all, some 20 partici-
pants, representing all relevant specialties (laboratory,
clinical, epidemiology, health services, etc.) and coming
from Cape Town, Durban, Pietermaritzburg, Johannes-
burg and Pretoria, anended the workshop.
In his welcoming remarks the chairman of the work-
shop, Professor A. D. Rothberg, (Department of
Paediatrics, Wits), recalled the conclusions reached at
the previous workshop and which would serve as a point
of departure for the present meeting. Delegates to the
previous workshop had agreed that data were insuffi-
cient to justify universal screening in South Africa;
screening programmes are unjustifiable unless they can
guarantee adequate follow-up and intervention in posi-
tive cases; and that collaboration between the State and
private laboratories regarding newborn hypothyroid
screening requires investigation in the quest for cost-
effective screening.
Professor W. J. Kalk (Department of Medicine,
Wits) presented the introductory talk on 'Screening for
congenital hypothyroidism' in which he provided the
following overview:
There is good evidence that congenital hypo-
thyroidism can be effectively treated in the majority of
cases, so screening for this condition appears to be
worth while. The reponed incidence ranges from 1 in
3 000 in Holland, to 1 in 12 000 in US blacks, with a
female preponderance (male:female =2:1). The causes
include thyroid dysgenesis (aplasia or hypoplasia) in
90% of cases; thyroid dyshormogenesis, with or with-
out a goitre at birth (1 in 30 - 50 000 live births); and
deficient TSH secretion (about 1 in 110 000 live
births).
False-positive diagnoses, when total thyroxine is used
to screen, can occur in babies with inherited deficiency
of thyroxine-binding globulin, which is found in 10 -
14000 births (M:F = 9:1). Prematurity, with low serum
T. but normal TSH levels is another imponant cause
(25% of cases in the USA) and is likely to be even more
frequent in our African populations.
Transient neonatal hypothyroidism is said to occur in
1 in 6 000 births in the USA, but has a reponed inci-
dence of up to 5% in areas of iodine deficiency in
Europe. Large areas of rural South Africa are iodine-
deficient, so transient hypothyroidism may be a signifi-
cant problem in local screening programmes. Iodine
deficiency is an imponant cause of cretinism, which
results from severe iodine deficiency early in intra-uter-
ine life: many cretins with permanent hypothyroidism
have circulating thyroid growth-blocking auto-anti-
bodies. Recent evidence points to transplacental transfer
of thyroid hormones in late pregnancy in humans, which
explains the presence of detectable T. in the serum of
athyreotic neonates, and may also explain why brain
development is not severely delayed in many of these
babies. This phenomenon, and the enhanced ability of
brain tissue to conven T 4 to tri-iodothyronine (T,) are
probably imponant in protecting the brain from the
deleterious effects of fetal hypothyroidism.
In developing screening progra=es for the detec-
tion of neonatal hypothyroidism in South Africa several
points must be borne in mind. Firstly, most babies are
discharged from obstetric units on the day of delivery -
later heel-prick blood sampling is not feasible. Secondly
and most importantly, facilities for the tracing and fol-
low-up of positive cases must be established. Thirdly,
data from the USA suggest that the initiation of thyro-
xine therapy per se does not necessarily lead to optimal
mental development in the hypothyroid infant: maternal
education and frequent biochemical follow-up are a
necessary pan of the 'screening package'.
Dr H. W. Hitzeroth (Genetic Services, Pretoria) then
put forward the proposed objectives of the workshop
which he suggested should be addressed either by way
of the individual presentations or during the panel dis-
cussion.
The self-explanatory titles highlight the contents of
the remaining presentations and of the workshop in
general, as follows: W. J. Zakolski (Department of
Chemical Pathology, SAIMR, Johannesburg): 'Thyroid
function tests using isotopic and non-isotopic methodo-
logical approaches'; C. Goldstone (Health and Housing
Directorate, City Council of Johannesburg), G. N.
Padayachee, A. D. Rothberg, L. Wagstaff and H. W.
Hitzeroth: 'Results of a co=uniry-based congenital
hypothyroid pilot screening progra=e'; F. Bonnici
(Depanment of Paediatrics and Medicine, Groote
Schuur Hospital, Cape Town), M. D. Mann, D. L.
Woods and A. Philotheou: 'The Cape Town screening
progra=e'; D. Winenberg (Department of Paedi-
atrics, University of Natal, Durban), T. Machanie and
G. M. B. Berger: 'Screening for congenital hypothy-
roidism at R K. Kahn Hospital in Durban'; J. J. Nel
(Genetic Services, Department of National Health,
Pretoria), P. Huner, J. van Dyk and H. W. Hitzeroth:
'Congenital hypothyroidism screening programme in
Pretoria: procedures and results'; representatives of pri-
vate chemical pathology laboratories, Drs Ferguson,
Roux and partners (Durban); Dr Pillay and partners
(Durban); Or Van Drimmelen and partners Gohannes-
burg); Drs Mauff, Zail and partners Gohannesburg):
'Congenital hypothyroidism screening in private prac-
tice: procedures and results'; J. van Dyk (Department
of Paediatrics, HF Verwoerd Hospital, Pretoria) and
C. W. Bredenkamp: 'Clinical follow-up of patients
positive on TSH and T 4 testing (the Pretoria screening
programme)'; F. Bonnici (Department of Paediatrics
and Medicine, Groote Schuur Hospital, Cape Town),




Panel discussion and recommen-
dations
All presentations, to a greater or lesser extent, centred
on the proposed objectives of the workshop and on
related questions. During the panel discussion the chair-
man again put these to the participants for more
thorough discussion and evaluation. The most impor-
tant viewpoints and recommendations that were put for-
ward are as follows:
Incidences
The screening results confirm that the incidence of con-
genital hypothyroidism in South African whites is com-
parable to incidences in Europe and North America, i.e.
about I in 4 000 newborns; tentative results for South
African Indians suggest the incidence to be higher and
for 'coloureds' probably lower than for whites. Whereas
published data for blacks elsewhere show the incidence
of hypothyroidism to be much lower than for whites, no
adequate data can as yet be presented for South African
blacks. This lack of epidemiological data is seen as a
major shortcoming that should urgently be addressed.
However, the abandonment of population classification
and the difficulty of effective follow-up of black new-
borns after a positive screening test, make this increas-
ingly problematic in present-day South Africa.
Clinical diagnosis
The participants were unanimous that diagnosis of con-
genital hypothyroidism by way of clinical signs/symp-
toms was generally inadequate and often too late to
allow effective treatment which would prevent the per-
manent, serious sequelae.
Clinical screening ofbabies
Following programmes in Canada and Cape Town to
routinely assess babies according to a schedule of select-
ed clinical signs/symptoms (during a home visit at about
6 weeks of age) - to score them in terms of a risk figure
and then to subject only high-risk cases to a laboratory
investigation - a Johannesburg team tested the feasibi-
lity of such an alternative procedure under local con-
ditions. After I year the results confirmed this to be nei-
ther a practical nor an effective alternative to routine
newborn screening.
The need for newborn screening
The participants unanimously agreed that from a medi-
cal point of view, there are very good reasons to subject
newborns of high-risk population groups to routine
laboratory screening for hypothyroidism. There is no
other effective way to make an early diagnosis and hence
facilitate early preventive treatment. For this reason, the
screening of newborns for congenital hypothyroidism
should be encouraged and extended in high-risk popula-
tion groups.
Private and/or state laboratory screening
The term 'state' in this context includes provincial and
provincially funded academic laboratories. Note was
taken of the fact that state health authorities can provide
newborn screening only on a vety limited scale. As far as
state funds can be made available for such screening
programmes these should primarily benefit people with
inadequate financial means (e.g. with no medical aid
insurance). In such cases the guidelines require that the
laboratory work be put on public tender for all qualify-
ing laboratories to participate (these will include private
and academiduniversity laboratories).
However, the rapidly growing demand by private
paediatricians and general practitioners for such labora-
tory tests is increasingly being met by private chemical
pathology laboratories. These are then usually paid for
by medical aid insurance schemes. Under the given cir-
cumstances this development is appropriate and wel-
comed, and needs to be extended. This will allow
increasing numbers of affected babies to be identified
and hence treated, thus preventing the permanent dis-
ability associated with this condition. However, concern
was expressed by some participants regarding the dis-
crepancy between the cost of the screening tests (about
R30) in private laboratories in South Africa, when com-
pared to the cost of mass screening in many overseas
countries and in South Africa. It was felt that this need-
ed to be addressed.
Among the difficulties experienced by the private
laboratories with screening for congenital hypothy-
roidism are that the quality of the blood-spots is not
always of the required standard, since the specimen col-
lections (by heel-prick on filter paper) are done by staff
members not under their control; and that very little
feed-back is received on the follow-up and final diagno-
sis of cases identified with the screening tests (which
lessens opportunities for quality control).
Laboratory technology
From the various presentations it appeared that a variety
of testing procedures and technologies are currently in
use for the detection of congenital hypothyroidism in
South Africa. These include the heel-prick (mainly
applied to cases referred by private doctors to private
laboratories), and the cord blood collection method -
thus requiring different laboratory methodologies. Tech-
niques highly divergent in sensitivity are also being used,
which entail differences in cut-off levels. Measuring the
TSH level was accepted as the most effective screening
test and the combination of TSH and T. as the most
effective diagnostic test. Whereas it is the prerogative of
each laboratory to apply the laboratory technology of its
choice, the participants were adamant that the labora-
tories should use the most accur;lte and up-to-date
methods currently available; this should include accept-
able quality control procedures.
Treatm.ent by specialised centres
The participants at the workshop strongly recommend-
ed that babies affected by congenital hypothyroidism
should be referred to recognised, specialist treatment
centres. The unanimous feeling was that only in this
way will it be possible to ensure effective long-term
treatmentlmanagement of the baby. This should include
regular evaluations, checks on compliance and conti-
nuous counselling.
National record-keeping
Following the example set in the USA and elsewhere, it
was felt that efforts to implement a national database for
congenital hypothyroidism screening should continue.
The minimum objective would be to compile data on
the overall numbers screened and positive cases identi-
fied. This would obviously require the voluntary co-
operation of all the screening laboratories. A more ambi-
tious objective would be to keep records of all patients
diagnosed and under treatment (together with some
appropriate clinical data). However, some participants
expressed concern about the practical feasibility and
desirability of such a detailed level of record-keeping.
-=-------------------------------""---I
Improved education and level of aware-
ness
The participants at the workshop expressed unreserved
suppon for the promotion of newborn screening for
congenital hypothyroidism by appropriate educational
campaigns, directed at medical target groups Oabora-
tories, paediatricians, etc.). In addition, the lay public
should also be alerted to the option of newbom screen-
ing and the benefits which these tests can hold. In par-
ticular, it was felt that the fa.mil.ies with an affected baby
urgently needed practical information on congenital
hypothyroidism and its treatment/prevention in order to
complement and suppon the medical intervention. It
was suggested that the Genetic Services of the
Depanment of National Health should address this
need, in consultation with all interested parties.
Follow-up workshop
To keep up the momentum and to evaluate progress,
everybody agreed that a follow-up workshop in 2 - 3
years' rime with appropriate repon-back and exchange
of experiences, would be highly desirable. A very signifi-
cant feature of this workshop was the fact that private
pathology laboratories were represented and contributed
substantially to its success. It was felt that this momen-
rum of co-operation should be maintained so that
screening for congenital hypothyroidism in South Africa
could become as effective and comprehensive as possi-
ble.
Participants
F. Bonnici (Cape Town), A. S. Botha (pretoria), J D.
Carrwright (Johannesburg), C. A. Goldstone (Johannes-
burg), H. W. Hirzeroth (pretoria), P. Huner (pretoria),
M. Jordaan (Johannesburg), W. J Kalk (Johannesburg),
M. A. King (Durban), J J. Nel (Pretoria), C. E.
Niehaus (pretoria), T. Padayachi (Durban), A. Price
(Johannesburg), A. D. Rothberg (Johannesburg), L. A.
van der Walt (Johannesburg), J c. van Dyk (pretoria),
D. F. Wittenberg (Durban), S. Zail (Johannesburg), W.
J. Zakolski (Johannesburg).
The workshop was sponsored by Diagnostic Products
and the Weil Organisation. Convened and reported by H.
W. Hiueroth, Department of National Health (Genetic
Services).
TABLE I.
Congenital hypothyroidism screening data for 1990,
1991 and 1992
Population Positive Confirmed No feed-
group Screened on screen positive back
1990
Blacks 514 3 0 0
Whites 9426 332 3 0
Asians 1396 8 1 0
CoIoureds 919 19 0 0
Not specified 1704 0 0 0
--- -- - -
Total 13959 362 4 0
1991
Blacks 1763 24 0 0
Whites 9000 262 3 0
Asians 2835 10 0 0
Coloureds 470 7 0 0
Not specified 8372 70 2 5
--- -- - -
Total 22440 373 5 5
1992
Blacks 2003 42 0 0
Whites 7883 308 3 0
Asians 930 3 0 0
Coloureds 380 8 0 0
Not specified 17950 91 0 83
--- -- - -
Total 29146 452 3 83
Notes
1. The data are based on screening tests done by the following laboratories!
departments. and are compiled and presented here with due acknowledgement
to these: Department of Chemical Pathology, University of Pretoria, and Or Du
Buisson and partners (Pretoria), both on behalf of Genetics Services,
Department of National Health (Pretoria); Department of Chemical Pathology,
and of Paediatrics and Child Health, University of Natal (Durban), on behaff of
Genetic Services, Department of National Health (Pretoria); Drs Ferguson,
Bouwer and partners (DUrban); Or Pillay and partners (Johannesburg); Drs
Mauff, lail and partners (Johannesburg); Or Van Drimmelen and partners
(Johannesburg); Drs Penman, Kock and Knight (Cape Town); Drs Dielrich and
Street (Cape Town). Data on the screening programme conducted by the
Department of Chemical Pathology, Red Cross Children's Hospital (Cape Town)
is not included in the present compilation.
2. The following qualifications need to be considered when evaluating the statis-
tical data: some laboratories only began screening in the course of 1990; in the
course of 1991 two more laboratories began with screening tests; in 1992 two
more laboratories began screening. The recorded figures for 1992 cover only
part of that year.
3. The varying numbers shown as 'positive on screen' largely renecl different
laboratory technologies and levels of sensitivity (cut-<>ff levels for TSH, etc.) as
used by the respective laboratories.
4. The numbers shown as 'population group not specified' follow from the fact
that this criterion of recording is being phased out
5.Two of the 3 wMe 'confimned positive' cases in 1991 are newboms who initially
were part of a 'population group not specified' screening cohort, on recall and
retesting they were identified as whITe babies.
6. For the 'no feed-back' group no final diagnosis could be provided, mainly
because the private chemical pathology laboratories are nOJ always explicitly
involved with the follow·up or informed of the final diagnosis.
